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Abstract 
Drug design is a costly and difficult process. Drug must fulfill several criteria of being active, non-
toxic and bioavailable. The conventional way of synthesizing drugs is a monotonous process. But 
computer aided drug design is a proficient way to overcome the tedious process of conventional 
method. Drugs can be designed computationally by structure or target based drug designing (SBDD). 
This review summarizes the methods of structure based drug design, usage of related softwares and a 
case study that explores to find a suitable drug (lead) molecule for the mutated state of H-Ras protein 
in order to prevent complex formation with Raf protein. 
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Introduction 
Traditionally, new drugs were generated from 
plants and other natural products through 
accidental observations and discoveries. Leads 
for new drug were generated from screening of 
organic compounds. Increasing information on 
the three dimensional structure of the biological 
target has paved path for structure based drug 
design. The rapid progress in the field of 
genomic, proteomic, and structural biology has  
increased the opportunities for future drug lead 
discovery. The antihypertensive drug, captopril, 
an angiotensin-converting enzyme (ACE) 
inhibitor was the first success story in structure- 
based drug design [1]. 
 
Kubinyi  has reviewed success stories of 
structure based drug design in the search for 
new, potent and selective HIV protease 
inhibitors, thrombin inhibitors, neuraminidase 
inhibitors and integrin receptor antagonists [1]. 
Anderson in his review paper mentioned that 
two of the first drugs to reach the market using 
SBDD were Amprenavir and Nelfinavir 
developed against HIV protease [2]. Structure- 
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based drug design can successfully contribute 
to the discovery process at different stages. It 
can be used at a very early stage at which no 
leads are available [3]. 
 
1. Overview of the Process 
 
Proteins 3D structures are generally used by 
SBDD to assist for the development and design 
of new lead (drug compounds). The overall 
process of SBDD (figure 1) would be divided 
mainly into two parts: 
 
a. Docking Ligands 
 
Proteins are flexible molecules and they adjust 
their shape to place bound ligands through 
rotation of bonds. SBDD allows to dock 
ligand/drug molecules into protein active sites 
and to visualize the movement that occurs in 
amino acid side chains. 
 
b. Lead  Optimization 
 
Lead optimization is a technique of refining 3D 
structures of drug molecules and it promotes 
the binding of drug to protein active sites. In 
this technique, researches gradually modify the 
structure of the drug compound by docking 
every specific structure of a drug compound in 
active site of protein, and calculating their 
extent of interactions. 
!
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Fig.1: The Outline of Structure-Based Drug Design 
 
2. Design Process 
a. Choice of drug target 
The target should be closely linked to cause of 
human disease and binds to a small molecule, 
generally a protein, in order to carry out a 
function. Drug target are usually protein having 
a well-defined binding pocket. SBDD against 
RNA targets with well-defined secondary 
structure has also been effective [2]. 
After the identification of target, structure can 
be determined following any of the methods: 
1.   X-ray crystallography 
2.  Nuclear magnetic resonance Spectroscopy 
(NMR) 
3.   Computational methods (Modelling) 
4.   Atomic Force Field Microscopy (AFM) 
 
3. Drug Design Methods 
Once identification of structure and target site 
is completed, there are number of ways to 
develop lead based on the structure of the target 
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which can be categorized as computer aided 
versus experimental. In experimental method, 
high-throughput screening is performed with 
combinatorial chemistry and thousands of 
molecules are tested for biochemical effects. 
Computer-aided methods can be classified into 
3 categories. 
a.   Database searching and docking methods 
b.   De novo drug design methods 
c.   Ligand binding scoring functions 
 
a. Database searching and docking methods 
 
Widely  used computational docking methods 
are DOCK, CONCORD, AUTODOCK, FLO98 
and FLEXX. DOCK systematically attempts to 
fit each compound from a database to the target 
structure’s binding site in such a way that in the 
database, three or more atoms of the molecule 
overlap with a set of predefined site points in 
the target binding site [7]. The default method 
for site point generation involves creating an 
inverse surface of the binding site. This is 
specified by the set of overlapping spheres that 
fill the binding site and touch the molecular 
surface at two points. The sphere centers (for 
all spheres with radii within a specified range) 
are used as site points. CONCORD is based on 
the combination of geometry rules and 
optimization methods. It selects lowest energy 
conformer of the molecule then scores on grid 
using different energy functions. On the basis 
of precalculated values for protein, each match 
is scored on a grid throughout the binding site 
of target molecule [7]. 
 
b. De novo drug design methods 
 
Structure based drug designing methods rely 
exclusively on ligand optimization approach 
based on the study of protein active site 
properties. There are three important categories 
of computational methods for the de novo 
design of structure based ligands: fragment 
positioning methods, molecule growth 
methods, and fragment methods coupled to 
database searches [6]. 
 
Fragment positioning methods 
 
Basically these methods are based on the 
selection of structures of individual functional 
groups or fragments from predefined library 
which fill the active site of enzyme [5]. Two 
well-known programs which predict 
energetically favorable binding site positions 
for chemical fragments are GRID and MCSS   
(Multiple Copy Simultaneous Search). GRID 
calculates protein interaction energies for 
functional groups on a grid surrounding the 
target structure. It includes non-bonded 
interaction like hydrogen bonding, electrostatic 
and Van der Waals. It is mainly useful for 
modifying existing lead compounds. Limitation 
of GRID is that the sphere probe must be 
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capable of making hydrogen bonds and must 
not be in a linear arrangement [6]. In MCSS 
method, the probes are fully flexible and 
individual atoms are represented by CHARMM 
potential energy function. The de novo drug 
designing approach involves three steps [6]. 
Initially it uses fragment positioning method. 
Secondly, clustering and connecting the 
optimally placed molecular fragments to form 
chemically sensible candidate ligands. Finally, 
depicts the binding of proposed compounds 
with another and to existing drugs. 
 
Molecule growth methods 
 
A fragment is fitted in the binding site of the 
target structure while ligand molecule is 
successively built by bonding a further 
fragment to it. There are various molecule 
growth methods are available, including SMoG 
(Small Molecule Growth), GrowMol, 
GroupBuild and GenStar. 
SMoG uses simple model for ligand-protein 
interactions as well as a knowledge-based 
potential. A large number of structures are 
statistically analyzed by an efficient Monte 
Carlo molecular growth algorithm that 
generates molecules through the adjoining of 
functional groups directly in the binding region 
[7]. 
GrowMol generates ligand structures from a 
library of atom as well as small functional 
group types and is scored based on its chemical 
complementarities with nearby atoms to the 
binding site of the target. GroupBuild is similar 
to GrowMol, it uses a predefined library of 
chemical fragments and scores candidate 
fragment positions depending on force field to 
get candidate small molecule ligands fragment 
by fragement. GenStar generates chemically 
reasonable structure which fills active site of 
enzyme. The proposed molecules provide good 
steric contact with the enzyme and also exist in 
low energy conformation. These structures 
consist of sp3 hybridized carbons which are 
grown sequentially, but which can also branch 
or form rings. Atoms  are grown from 
predocked inhibitor core. For each new atom 
generated by the program, several hundred 
candidate positions representing a range of 
reasonable bond lengths, bond angles, and 
torsion angles are considered. Then, each 
candidate is scored, with a simple enzyme 
contact model. From the highest scoring cases, 
positions are chosen at random.  Duplicate 
structures may be removed applying variety of 
criteria. Energy of compounds may be 
minimized and displayed using standard 
modeling programs. 
 
Fragment methods coupled to database 
searches 
 
It is an integrated approach for fragment 
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positioning methods and database searching 
techniques   either to extract those existing 
molecules from a database that can be docked 
with the preferred fragments in their most 
favorable positions into the binding site or for 
de novo design. HOOK generates a database of 
molecular skeletons without involving 
functional groups on the database molecules 
and then fit molecular skeletons into the target 
binding site such that two MCSS functional 
group minima can be hooked by using docking. 
Then, it undergoes geometrical   superposition 
of two designated hooks in the skeletal 
molecules and finally using inverted Lennard-
Jones type contact potential, the fit of the 
skeleton in the binding site in two functional   
group minima, is scored. After validating 
scores, secondary searches are carried out to 
attach additional MCSS minima to the skeleton, 
if fit is acceptable [6]. CAVEAT is 
comparatively faster method due to 
consideration of interaction between the 
skeletal molecule and the binding site in post 
processing step. It is similar to HOOK in that it 
involves searching of a database of three-
dimensional structures of small cyclic 
molecules to connect optimally placed 
fragments in the binding site. In the database, 
specific bonds of each molecule are represented 
as vectors, and the molecule is specified as a 
set of pairwise combinations of bond vectors. It 
finds matches between pairs of bond vectors 
from the fragments of the query molecules and 
the database molecules [6]. 
 
c. Ligand binding scoring functions 
 
The ligands binding scoring functions are 
major determinant of the accuracy of scoring 
functions that ranks the lead compounds. 
Factors which contribute to ligand binding 
include hydrophobic effect, dispersion 
interactions, hydrogen bonding, other 
electrostatic interactions and solvation effects. 
With increasing complexity, the various 
approaches for estimating binding affinities 
include scoring functions based on statistical 
analysis of known structure of protein ligand 
complexes, physicochemical properties, force 
field calculations, force field calculation with 
added solvation corrections and free energy 
perturbation (FEP) calculations. SMoG pseudo 
energy function is a scoring function based on 
statistical analysis of high resolution X ray 
structure. Currently knowledge based, 
regression based and first principle based 
methods have been developed to rank lead 
compounds [8]. 
 
 
4. Case Study 
 
In the Ras subfamily, mainly K-RAS, H-RAS 
and N-RAS codes for those proteins which are 
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made up of 189 amino acids with molecular 
weight 21kDA protein [9]. Guanosine 
nucleotide binding protein or G-proteins works 
in form of signaling switches with two states 
that are active and inactive. Usually it is bound 
to the nucleotide GDP in the inactive state. On 
the other hand, it is bound to GTP in the active 
state. Guanine nucleotide exchange factors 
(GEFs) and GTPase activating proteins (GAPs) 
are mainly used in exchanging the bound 
nucleotide. Ras is associated with an intrinsic 
GTPase activity in which it can hydrolyze 
bound GTP into GDP. But, due to its less  
efficiency, RasGAP is needed which is formed 
by binding of Ras and GAP and stabilizes the 
Ras catalytic residues by releasing inorganic 
phosphate and ultimately leads to Ras molecule 
in GDP bound state for Ras inactivation. It has 
been found that mutations in the Ras family of 
proto-oncogenes are very commonly observed 
in 20% to 30% of all human tumors [10].The   
inappropriate activation of the gene affects 
malignant transformation, proliferation and 
signal transduction [11], due to which, the 
mutated Ras P21  has a structure that disables 
its ability to bind with GTPase activating 
protein (GAP) and creates an 
autophosphorylation site, keeping the Ras P21 
in the GTP-bound activate state and 
contributing to a malignant cell phenotype [12, 
13]. 
In this context, target-based drug discovery is 
considered to be highly potential. The mutated 
H-Ras is perceived to be an important target to 
treat colorectal and pancreatic cancer. A 
suitable drug (lead) molecule can be searched 
for the mutated state of H-Ras protein in order 
to prevent complex formation with Raf protein.  
 
a. Materials and Methods 
 
The protein structures of H-RAS P21 mutant 
(PDB ID - 521P) and of Ras-binding domain 
(PDB ID-1WXM) were taken from Protein 
Data Bank 
http://www.rcsb.org/pdb/home/home.do. 
There were two methods used to predict 
potential binding site. 
In the first approach, screening of ligand 
molecules was carried out through BLAST 
search engine by submitting the mutated HRas 
(PDB ID: 521P) protein sequence to DrugBank 
database: 
http://redpoll.pharmacy.ualberta.ca/drugbank/dr
ugBlast.htm. The DrugBank search showed 
trifluoroethanol, S-oxymathionine and 
isopropanol as active ligands. 
In a second approach, ChemBank ligand entries 
were downloaded  from Ligand in 
SDF format and entries of ligand was used for 
virtual screening and docking into effectors 
region of mutated H-Ras by using Discovery 
Studio/LigandFit program to identify active 
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potential drugs. The Ligand Fit docking 
algorithm produced 10 different hits of ligand, 
such as YS035, nizatidine, leuhistin, 3-
aminopropanesulphonic acid, guanidine, 
acetamide, methoxamine, urea, aluminum 
fluoride and hydroxyurea from two different 
binding site cavities that were encompassed in 
effectors region of mutated H-Ras. 
 
5. Results and Discussion 
 
Leaving all the other molecules, the 3-
aminopropanesulphonic acid was docked with 
energy of -0.009 kcal/mol and hydroxyurea 
with -3.014 kcal/mol. These two ligand 
molecules were also found to obey the 
Lipinski’s rule of five. This Rule evaluates 
drug ability, or finds a chemical compound 
with some particular pharmacological 
properties that can make it an orally active drug 
in humans. 
 
This result correlates well with  earlier 
experimental results [14, 15] and it depicts that 
the identified binding conformations of these 
inhibitors are reliable and produce anti-tumor 
effects in a variety of solid tumor [16] and 
leukemia. 3-aminopropanesulfonic acid is a 
synthetic   gammaaminobutyric acid (GABA) 
analog. Hydroxyurea is an antineoplastic agent 
that produces anti-tumor effects in animals and 
man in a various forms of solid tumor and 
would be an effective drug to inhibit function 
of mutant H-Ras P21 protein, which will be 
able to arrest cell growth and cancer cell 
proliferation. From this study and previously 
reported experimental data in literature, we 
observe that hydroxyurea and 3-
aminopropanesulphonic acid would be an 
effective drug to inhibit function of mutant H-
Ras P21 protein, which will in turn arrest the 
process of cell growth and proliferation of the 
cancer cell [17]. It was earlier reported that the 
oral administration of hydroxyurea to 20 
patients with chronic myelogenous leukemia, 
resulted in the decrease count of white blood 
cell [18]. 
 
Conclusion 
 
The major goal of structure-based drug design 
is to develop an efficient process that involves 
a high resolution crystal structure of validated 
biological target molecules and reliably 
generates an easily synthesized, high affinity 
small molecule with desirable pharmacological 
properties. New advancement in the field of 
structural genomics, proteomics and 
bioinformatics will enhance variety of 
approaches for structure based drug design. 
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